

The first patients are included in the US clinical trial for ASTar

Q-linea AB (publ) (OMX: QLINEA) – Q-linea announces today that the US study for ASTar® is entering the final phase and that the first patient samples now have been included.

The ASTar Instrument and ASTar BC G- Kit offer the broadest combination of antimicrobials and dilution ranges in a single analysis for Gram-negative bacteria. The test enables the analysis of both fastidious and non-fastidious bacteria, for rapid fully automatic and comprehensive results that support optimal treatment decisions.

"We are delighted to announce that we now have started to include patient samples in the US clinical study for ASTar. The clinical study contains three parts where the prospective part is the last. We have installed ASTar at three US hospitals and they will collect up to 150 patient samples each. Considering the size of the hospitals, we believe that the prospective part should be completed in the beginning of next year.", says Jonas Jarvius, CEO of Q-linea.

ASTar Instrument and ASTar BC G- Kit is CE-marked but not FDA 510(k)-cleared and not available for sale in the US.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB Jonas.Jarvius@qlinea.com +46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB Anders.Lundin@qlinea.com +46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

The first patients are included in the US clinical trial for ASTar